MedPath

COMPARATIVE STUDY ON THE EFFICACY OF YASHTIMADHU GRANULES AND YASHTIMADHU CHURNA IN ENHANCING IQ IN ADOLESCENT

Phase 3
Not yet recruiting
Conditions
APPARENTLY HEALTHY VOLUNTEERS
Registration Number
CTRI/2025/04/085457
Lead Sponsor
PGIA DSRRAU Jodhpur
Brief Summary

- This summary is for a clinical trial comparing Yashtimadhu granules and churna to enhance IQ in school-going children aged 16–20.

- The study involves 150 participants, randomized into two groups with different doses.

- Research suggests it’s an open-label, 45-day study with assessments every 15 days.

- The evidence leans toward measuring IQ with the Wechsler Adult Intelligence Scale (WAIS).

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
150
Inclusion Criteria

Apparently healthy subjects between age group of 16 yrs to 20 yrs with IQ score ranging 80-109 (scores obtained after conducting verbal & performance sub-tests) will be included irrespective of their sex & socio-economic status.

Exclusion Criteria
  • Subjects below 16 years & above 20 years of age.
  • Subjects suffering from any systemic disorders.
  • Subjects with learning disorders & any genetic disorder.
  • Subjects with history of hypersensitivity to any of the trial drug and its ingredients.
  • Subjects who are not willing to participate in the study.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of Yashtimadhu (SAT-F.484) Granules & Yashtimadhu (SAT-F.484) Churna to boost intelligence in adolescents.IN 45 DAYS
Secondary Outcome Measures
NameTimeMethod
To enhance intelligent quotient in subjects.To study the concept of Medha (SAT-D.6344).

Trial Locations

Locations (1)

HOSPITAL PGIA DSRRAU JODHPUR

🇮🇳

Jodhpur, RAJASTHAN, India

HOSPITAL PGIA DSRRAU JODHPUR
🇮🇳Jodhpur, RAJASTHAN, India
Dr Shubham Attarkar
Principal investigator
8605131642
mr.shubhamattarkar97@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.